Applications

1380 – BRCA mutation testing to determine eligibility for olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome Supported

Application details

Reason for application

New MBS item.

Service or technology in this application

Genetic testing for BRCA1 and BRCA2 mutations in patients with platinum-sensitive relapsed ovarian cancer, to determine PBS eligibility for treatment with olaparib (co-dependent technology).

Type: Co-dependent technology

Medical condition this application addresses

Ovarian cancer is the tenth most common cancer in Australian women, and the second most common gynaecological cancer. The symptoms for ovarian cancer tend to be vague and non-specific. The majority of women with ovarian cancer are diagnosed at an advanced stage after the tumour has spread to other organs, with the prognosis associated with advanced ovarian cancer being limited.

Meetings to consider this application

  • PASC meeting: 
    • 14 - 15 August 2014
    • 11 - 12 December 2014
  • ESC meeting: 10 - 11 February 2016
  • MSAC meeting: 
    • 30 - 31 March 2016
    • 24 - 25 November 2016